多柔比星联合帕博利珠单抗治疗晚期未接受蒽环类药物的肉瘤:1/2期非随机临床试验评估
这项单中心1/2期非随机试验评估多柔比星联合帕博利珠单抗在37例晚期未接受蒽环类药物的肉瘤患者中的安全性和疗效。联合方案耐受良好,未观察到剂量限制性毒性;二期部分客观缓解率为13%,总体为19%,中位无进展生存期8.1个月,中位总生存期27.6个月。尽管主要终点未达到,但生存数据与既往研究相比具有优势。
要点
- 多柔比星联合帕博利珠单抗在晚期肉瘤中耐受良好,未出现剂量限制性毒性。
- 二期部分客观缓解率13%,总体19%;中位无进展生存期8.1个月,中位总生存期27.6个月。
- 去分化脂肪肉瘤和未分化多形性肉瘤中观察到持久部分缓解,值得进一步研究。
核心结论
- 多柔比星联合帕博利珠单抗耐受良好,虽未达到客观缓解率主要终点,但无进展生存期和总生存期与既往发表研究相比具有优势。
研究设计与样本
- 单中心、学术性肉瘤专科中心开展的非随机临床试验,采用两阶段2期设计,共治疗37例晚期未接受蒽环类药物的肉瘤患者(22男15女),中位年龄58.4岁(范围25-80)。
- 允许除骨肉瘤、尤文肉瘤、腺泡型和胚胎型横纹肌肉瘤以外的所有肉瘤亚型入组;测试多柔比星45和75 mg/m2两个剂量水平联合帕博利珠单抗的安全性。
主要发现
- 联合方案耐受良好,无显著非预期毒性,未观察到剂量限制性毒性。
- 二期部分客观缓解率为13%,总体客观缓解率为19%;中位无进展生存期8.1个月(95%CI 7.6-10.8),中位总生存期27.6个月(95%CI 18.7-未达到)。
- 3例未分化多形性肉瘤中2例、4例去分化脂肪肉瘤中2例达到持久部分缓解。
临床怎么用
- 对于晚期未接受蒽环类药物的肉瘤患者,多柔比星联合帕博利珠单抗是耐受良好的治疗选择,尤其值得在未分化多形性肉瘤和去分化脂肪肉瘤中进一步研究。
局限性
- 非随机设计、单中心、样本量有限(37例),客观缓解率主要终点未达到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Anthracycline-based therapy is standard first-line treatment for most patients with advanced and metastatic sarcomas. Although multiple trials have attempted to show improved outcomes in patients with soft-tissue sarcoma over doxorubicin monotherapy, each has fallen short of demonstrating improved outcomes. OBJECTIVE: To evaluate the safety and efficacy of doxorubicin in combination with pembrolizumab in patients with advanced, anthracycline-naive sarcomas. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized clinical trial used a 2-stage phase 2 design and was performed at a single, academic sarcoma specialty center. Patients were adults with good performance status and end-organ function. Patients with all sarcoma subtypes were allowed to enroll with the exception of osteosarcoma, Ewing sarcoma, and alveolar and embryonal rhabdomyosarcoma. INTERVENTIONS: Two dose levels of doxorubicin (45 and 75 mg/m2) were tested for safety in combination with pembrolizumab. MAIN OUTCOMES AND MEASURES: Objective response rate (ORR) was the primary end point. Overall survival (OS) and progression-free survival (PFS) were secondary end points. Correlative studies included immunohistochemistry, gene expression, and serum cytokines. RESULTS: A total of 37 patients (22 men; 15 women) were treated in the combined phase 1/2 trial. The median (range) patient age was 58.4 (25-80) years. The most common histologic subtype was leiomyosarcoma (11 patients). Doxorubicin plus pembrolizumab was well tolerated without significant unexpected toxic effects. The ORR was 13% for phase 2 patients and 19% overall. Median PFS was 8.1 (95% CI, 7.6-10.8) months. Median OS was 27.6 (95% CI, 18.7-not reached) months at the time of this analysis. Two of 3 patients with undifferentiated pleomorphic sarcoma and 2 of 4 patients with dedifferentiated liposarcoma had durable partial responses. Tumor-infiltrating lymphocytes were present in 21% of evaluable tumors and associated with inferior PFS (log-rank P = .03). No dose-limiting toxic effects were observed. CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, doxorubicin plus pembrolizumab was well tolerated. Although the primary end point for ORR was not reached, the PFS and OS observed compared favorably with prior published studies. Further studies are warranted, especially those focusing on undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02888665.
引用
- Pollack SM, Redman MW, Baker KK, et al. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial. JAMA Oncol. 2020. PMID: 32910151. doi:10.1001/jamaoncol.2020.3689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。